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OBJECTIVE—Mesenchymal stem cells (MSCs) have been re-
ported to secrete various cytokines that exhibit angiogenic and
neurosupportive effects. This study was conducted to investigate
the effects of MSC transplantation on diabetic polyneuropathy
(DPN) in rats.
RESEARCH DESIGN AND METHODS—MSCs were isolated
from bone marrow of adult rats and transplanted into hind limb
skeletal muscles of rats with an 8-week duration of streptozoto-
cin (STZ)-induced diabetes or age-matched normal rats by uni-
lateral intramuscular injection. Four weeks after transplantation,
vascular endothelial growth factor (VEGF) and basic ﬁbroblast
growth factor (bFGF) productions in transplanted sites, current
perception threshold, nerve conduction velocity (NCV), sciatic
nerve blood ﬂow (SNBF), capillary number–to–muscle ﬁber ratio
in soleus muscles, and sural nerve morphometry were evaluated.
RESULTS—VEGF and bFGF mRNA expression were signiﬁ-
cantly increased in MSC-injected thigh muscles of STZ-induced
diabetic rats. Furthermore, colocalization of MSCs with VEGF
and bFGF in the transplanted sites was conﬁrmed. STZ-induced
diabetic rats showed hypoalgesia, delayed NCV, decreased
SNBF, and decreased capillary number–to–muscle ﬁber ratio in
soleus muscles, which were all ameliorated by MSC transplanta-
tion. Sural nerve morphometry showed decreased axonal circu-
larity in STZ-induced diabetic rats, which was normalized by
MSC transplantation.
CONCLUSIONS—These results suggest that MSC transplanta-
tion could have therapeutic effects on DPN through paracrine
actions of growth factors secreted by MSCs. Diabetes 57:
3099–3107, 2008
D
iabetic polyneuropathy (DPN) is the most com-
mon complication of diabetes. It is estimated
that 20–30% of diabetic patients are affected
by symptomatic DPN (1). Generally, DPN de-
velops symmetrically in a length-dependent fashion, with
dying back or dropout of the longest nerve ﬁbers; both
myelinated and unmyelinated, large and small are affected.
Diabetic patients suffer from various symptoms of DPN,
such as spontaneous pain, hyperalgesia, and diminished
sensation (2). It has been shown that tight glycemic
control is effective in slowing the progression of DPN but
cannot completely prevent it (3). Therefore, additional
therapeutic strategies are required.
Neural cell degeneration and decreased nerve blood
ﬂow (NBF) have been recognized as pathophysiologically
characteristic features of DPN (4). Therefore, therapeutic
agents that could act as both neurotrophic and angiogenic
factors would be useful for the treatment of DPN even at
an advanced stage. We previously demonstrated that local
administration of basic ﬁbroblast growth factor (bFGF) by
intramusclar injection with crosslinked gelatin hydrogel
improved the impaired nerve functions of streptozotocin
(STZ)-induced diabetic rats, including amelioration of de-
creased NBF, hypoalgesia, and the delayed motor nerve
conduction velocity (MNCV) on the treated side of sciatic-
tibial nerves and that these effects were maintained for at
least 30 days (5). Schratzberger et al. (6) showed that
vascular endothelial growth factor (VEGF) gene transfer
signiﬁcantly increased the NCV and NBF as well as the
vascular densities in muscle and peripheral nerve, suggest-
ing that the induction of local angiogenesis by VEGF
ameliorated experimental DPN. Thus, angiogenic cyto-
kines such as bFGF and VEGF could be potential agents
for the treatment of DPN.
Mesenchymal stem cells (MSCs) reside in the bone
marrow stromal fraction, which provides the cellular mi-
croenvironment supporting hematopoeisis. MSCs were ﬁrst
described as bone-forming progenitors from the stromal
fraction of rats by Friedenstein et al. (7) in 1966. Because
MSCs have an adherent nature, they are expandable in
culture, and it is relatively easy to obtain a sufﬁcient number
of cells for cell therapy. MSCs have recently been shown to
differentiate into multilineage cell types (8,9) and to secrete
various cytokines, including bFGF and VEGF (10–13).
Through these actions, transplantation of MSCs has been
experimentally reported to be a promising strategy for the
treatment of ischemic diseases such as myocardial infarction
and arteriosclerosis obliterans. Consequently, we hypothe-
sized that MSC transplantation would ameliorate DPN. This
is the ﬁrst report that demonstrates the therapeutic effects of
MSC transplantation on DPN.
RESEARCH DESIGN AND METHODS
Animals and induction of diabetes. Six-week-old male Sprague-Dawley rats
(Chubu Kagakushizai, Nagoya, Japan) with an initial body weight of 170–180
g were allowed to adapt to the experimental animal facility for 7 days. They
were housed in an aseptic animal room at a temperature of 20–24°C and a
humidity of 40–70%, with a 12-h light cycle and 12 fresh air changes per hour, and
were allowed free access to rat diet and water. Diabetes was induced by
intraperitoneal injection of STZ (60 mg/kg; Sigma Chemical, St. Louis, MO).
Control rats received an equal volume of citric acid buffer. One week after STZ
administration, rats with plasma glucose concentrations of 16 mmol/l were
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DIABETES, VOL. 57, NOVEMBER 2008 3099selected as the STZ-induced diabetic group. The Nagoya University Institutional
Animal Care and Use Committee approved the protocols of this experiment.
Isolation and expansion of MSCs. Bone marrow was harvested by ﬂushing
the tibiae and femurs of adult male Sprague-Dawley rats (200–250 g body wt)
with PBS. Mononuclear cells (MNCs) were isolated from the collected marrow
using the Histopaque-density centrifugation method (14). Total MNCs were
cultured in Dulbecco’s modiﬁed Eagle’s medium, with 10% fetal bovine serum
(Sigma Chemical) on plastic dishes at 37°C in 5% humidiﬁed CO2. Nonadher-
ent cells were washed off, and adherent cells were expanded. When adherent
cells were conﬂuent (deﬁned as passage 0), they were continuously cultured
as MSCs until passage 3.
Characterization of MSCs. Cells were incubated with ﬂuorescein isothio-
cyanate–conjugated mouse monoclonal antibodies against rat CD90 (Becton
Dickinson, Franklin Lakes, NJ), ﬂuorescein isothiocyanate–conjugated ham-
ster anti-rat CD29 monoclonal antibody (Becton Dickinson), phycoerythrin-
conjugated mouse monoclonal antibodies against rat CD34 (Santa Cruz
Biotechnology, Santa Cruz, CA), and CD45 (Becton Dickinson) and were
characterized as MSCs by ﬂuorescence-activated cell sorting (FACSCalibur;
Becton Dickinson). Isotype-identical antibodies served as controls.
Labeling of MSCs. MSCs were labeled with the red ﬂuorescent dye PKH26
(Sigma Chemical) according to the manufacturer’s protocol, with minor
modiﬁcations. Brieﬂy, 2  10
7 MSCs were labeled by 2  10
5 to 2  10
6
mol/l PKH26 for 4 min at room temperature, and this reaction was terminated
by the addition of 2 ml fetal bovine serum. Cells were washed twice with 5 ml
Dulbecco’s modiﬁed Eagle’s medium and transplanted.
Transplantation of MSCs. Eight weeks after the induction of diabetes, 1 
10
6 cells/limb of MSCs in 1.0 ml saline were injected into the right thigh and
soleus muscles of normal and STZ-induced diabetic rats. Left hind limb
muscles were treated with saline alone. Four weeks later, the following
parameters were bilaterally measured.
Measurement of current perception threshold using the neurometer.
To evaluate the nociceptive threshold, the current perception threshold was
measured in 4, 8, and 12-week STZ-induced diabetic and age-matched normal
rats using a CPT/LAB neurometer (Neurotron, Denver, CO) according to the
method of Kiso et al. (15), with minor modiﬁcations. An electrode (SRE-0405-
8; Neurotron) for stimulation was attached to plantar surfaces of the rats. The
skin patch dispersion electrode (SDE-49-4; Neurotron) was applied to the
back of the body, where the hair had been removed with a hair clipper. Each
rat was kept in a Ballman cage (Natsume, Tokyo, Japan) suitable for light
restraint in the awake state. Transcutaneous nerve stimuli of three sine-wave
pulses (at 5, 250, and 2,000 Hz) were applied to the plantar surfaces of the rats.
The intensity of each stimulation was gradually increased automatically (incre-
ments of 0.05 mA for 5 and 250 Hz, increments of 0.1 mA for 2,000 Hz). The
minimum intensity at which each rat vocalized or was intensely startled with and
without vocalization was deﬁned as the current perception threshold. Five
consecutive measurements were conducted at each frequency. The current
perception thresholds were reported as the means of the values obtained at the
fourth and ﬁfth measurements because the threshold values obtained at the ﬁrst,
second, and third measurements slightly ﬂuctuated.
NCV. After intraperitoneal injection of sodium pentobarbital (5 mg/100 g), rats
were placed on a heated pad in a room maintained at 25°C to ensure a
constant rectal temperature of 37°C. The sciatic-tibial MNCV between the
ankle and sciatic notch was determined with a Neuropak NEM-3102 instru-
ment (Nihon-Koden, Osaka, Japan), as previously described (5,16,17).
NBF. After evaluation of the MNCV, sciatic NBF (SNBF) was measured by the
hydrogen clearance technique with an analog recorder (BW-4; Biochemical
Science, Kanazawa, Japan) and an electrolysis tissue blood ﬂow meter
(RBA-2; Biochemical Science), as previously described (5,16,17), and calcu-
lated with the equation of Koshu et al. (18). During this measurement, rats
were placed on a heated pad in a room maintained at 25°C to ensure a
constant rectal temperature of 37°C.
Tissue collection. Four weeks after the transplantation, rats were killed by
an overdose of pentobarbital (15 mg/100 g). Thigh muscles for RNA extraction
and the distal portions of sural nerves and soleus muscles for protein
extraction were obtained from normal and STZ-induced diabetic rats. Tissues
were snap-frozen in liquid nitrogen and kept at 80°C until use. Soleus
muscles were embedded within OCT compound (Sakura Finetechnical, To-
kyo, Japan), and cryostat sections were prepared for immunoﬂuorescence
analysis. The proximal portions of the sural nerves were ﬁxed and immersed
in 2.5% glutaraldehyde overnight. They were postﬁxed in osmium tetroxide,
dehydrated, and embedded in Epon for morphometric analysis. Normal and
STZ-induced diabetic rats were perfused with 500 ml of 4% paraformaldehyde
ﬁxative. After perfusion, the soleus muscles from both sides were immersed in
4% paraformaldehyde overnight, embedded in parafﬁn, and cut into 5-m
sections to evaluate the capillary number–to–muscle ﬁber ratio.
Immunoﬂuorescence and histological analysis. Four weeks after the
transplantation, for tracking of transplanted MSCs labeled by PKH26, cryostat
sections of the soleus muscles were observed using a ﬂuorescence micro-
scope. Then, to detect the colocalization of MSCs labeled by PKH26 and VEGF
or bFGF protein, immunoﬂuorescence staining was performed. Cryostat
sections of the soleus muscles were ﬁxed in 4% formaldehyde, blocked with
5% normal goat serum for 60 min, and incubated with rabbit anti-VEGF
polyclonal antibody (1:100; Santa Cruz Biotechnology) or rabbit anti-bFGF
polyclonal antibody (1:100; Santa Cruz Biotechnology) and then with Alexa
Fluor 488–coupled goat anti-rabbit IgG antibody (1:250; Invitrogen, Carlsbad,
CA). Finally, nucleus staining was performed using 4,6-diamidino-2-phenylin-
dole (DAPI; Wako, Osaka, Japan). Stained sections were observed using a
ﬂuorescence microscope, and merge images of PKH26 (red), growth factors
(green), and DAPI (blue) were obtained.
Measurement of nerve growth factor and neurotrophin 3 contents in
the soleus muscles. Nerve growth factor (NGF) and neurotrophin 3 (NT-3)
contents in the soleus muscles were determined with a quantitative two-site
enzyme immunoassay using the Emax Immunoassay System (Promega, Mad-
ison, WI). The assays were performed according to the manufacturer’s
protocols. Samples were homogenized in lysis buffer (137 mmol/l NaCl; 20
mmol/l Tris HCl, pH 8.0; 1% NP40; 10% glycerol; 1 mmol/l phenylmethyl
sulfonyl ﬂuoride; 10 g/ml aprotinin; 1 g/ml leupeptin; and 0.5 mmol/l sodium
vanadate) and centrifuged (14,000g for 30 min), and the supernatants were
loaded on MaxiSorp 96-well plates (Nalge-Nunc International, Rochester, NY)
precoated with anti-NGF or anti–NT-3 polyclonal antibodies. Each sample was
assayed in duplicate. Absorbance from colorimetric reactions of horseradish
peroxidase and TMB (3,3,5,5-tetramethyl benzidine) was determined by a
Powerscan HT (Dainippon Pharmaceutical, Osaka, Japan) microplate reader
(450 nm) and converted to NGF or NT-3 protein levels (pg/ml) by normalizing
to the standard curve. The recoveries of exogenous NGF and NT-3 added to
soleus muscle homogenates were measured, and the concentrations of NGF
and NT-3 were calculated, taking into account the recoveries. Results were
expressed as picograms per milligram protein.
mRNA expression of transplanted sites. RNA was extracted from frozen
samples of thigh muscles using Isogen (Nippon Gene, Toyama, Japan),
according to the manufacturer’s instructions and quantiﬁed spectrophoto-
metrically. Starting from 1 g RNA, cDNA was synthesized using ReverTra
Ace (Toyoba, Osaka, Japan), according to the manufacturer’s descriptions.
Primers and probes for VEGF, bFGF, and 18S rRNA for the endogenous
control were purchased from TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA). The probe for 18S rRNA was ﬂuorescently
labeled with VIC and TAMRA, whereas probes for the genes of interest were
labeled with FAM and TAMRA. Real-time quantitative PCR was performed and
monitored using the Mx3000P QPCR System (Stratagene, La Jolla, CA). The
PCR master mix was based on TaqMan Universal PCR Master Mix (Applied
Biosystems). In the same reaction well, cDNA samples (5 l, for a total volume
of 25 l per reaction) were analyzed both for the gene of interest and the
reference gene (18S rRNA) using a multiplex approach. Relative quantity was
calculated by the 2[DELTA]
[DELTA]Ct method (19).
Capillary number–to–muscle ﬁber ratio. The sections of soleus muscles
ﬁxed with paraformaldehyde were used for hematoxylin-eosin staining and
immunostaining. These stainings were performed as previously described in
detail (16). The vascular capillaries were stained by anti–von Willebrand factor
polyclonal antibody (1:600; Dako, Tokyo, Japan) and were counted under light
microscopy (200) to determine the capillary number–to–muscle ﬁber ratio. Five
ﬁelds from the each section were randomly selected for the capillary counts.
Morphometry of sural nerve. Proximal sural nerve sections were used for
morphometric analysis. Semithin cross-sections of the sural nerve were
stained with toluidine blue. Then, we assessed the total complement of sural
nerve myelinated ﬁbers and obtained the following parameters: fascicular area,
density of myelinated ﬁbers, occupancy rate, mean myelin area, mean axonal
area, axon-to-myelin ratio, axonal diameter, myelin thickness, and axonal circu-
larity (formula  4[area/perimeter {2}]) (20). These parameters were obtained
using image processing and analysis software ImageJ (Research Services Branch
of the National Institutes of Mental Health, Bethesda, MD).
Western blotting. The distal sural nerves were used for Western blotting.
Samples were lysed in detergent lysis buffer (20 mmol/l Tris-HCl, pH 7.5; 150
mmol/l NaC1; 1 mmol/l EDTA; 1 mmol/l EGTA; 1% Triton; 2.5 mmol/l sodium
pyrophosphate; 1 mmol/l 	-glycerophosphate; 1 mmol/l Na3VO4; and 1 g/ml
leupeptin). The lysates were centrifuged at 14,000 rpm for 20 min at 4°C, and
protein concentrations were measured using a bicinchoninic acid assay
(Sigma Chemical). Ten micrograms of protein were separated by 7.5–10%
SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica,
MA). Membranes were blocked with Tween-20 Tris-buffered saline (10 mmol/l
Tris-HCl, pH 7.5; 100 mmol/l NaCl; and 0.1% Tween 20) containing 5% nonfat
dry milk before incubation with mouse monoclonal anti–neuroﬁlament light-
chain (NF-L) antibody (1:5,000; Chemicon, Temecula, CA), rabbit polyclonal
anti–neuroﬁlament medium-chain (NF-M) antibody (1:10,000; Chemicon),
rabbit polyclonal anti–neuroﬁlament heavy-chain (NF-H) antibody (1:10,000;
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Antigen detection was performed using enhanced chemiluminescence West-
ern blotting detection reagents (Amersham Pharmacia Biotech, Piscataway,
NJ) with horseradish peroxidase–conjugated secondary antibodies. Images
were scanned and densities were determined by ImageJ. The expression of
proteins was corrected for by actin density, and the expression in the limbs of
normal rats treated with saline was arbitrarily set at 1.0.
Statistical analysis. All the group values were expressed as means 
 SD.
Statistical analyses were made by a one-way ANOVA, with the Bonferroni
correction for multiple comparisons.
RESULTS
Clinical ﬁndings. At 8 weeks, STZ-induced diabetic rats
showed severe hyperglycemia (normal rats [n  10]: 5.6 

0.7 mmol/l, STZ-induced diabetic rats [n  11]: 24.4 
 1.4
mmol/l; P  0.0002) and signiﬁcant reductions in body
weight (normal rats [n  10]: 516 
 26 g, STZ-induced
diabetic rats [n  11]: 294 
 32 g; P  0.0004).
Characterization of cultured MSCs. Most cultured ad-
herent cells showed the ﬁbroblastic morphology that is
characteristic to MSCs. Although they expressed CD29
and CD90, a majority of adherent cells were negative for
CD34 and CD45, which is consistent with MSCs previously
reported (8,21).
Tracking of transplanted MSCs. Four weeks after the
transplantation, MSCs labeled with red ﬂuorescent dye
PKH26 resided in the gaps between muscle ﬁbers (Fig. 1).
As far as we could observe, they kept their features and
did not participate in the tissue structures, such as blood
vessels, muscles, and nerve ﬁbers.
Local production and secretion of bFGF and VEGF.
bFGF and VEGF mRNA expressions in MSC-injected thigh
muscles of 12-week STZ-induced diabetic rats signiﬁcantly
increased by 1.79- and 1.62-fold, respectively, compared
with those in saline-injected thigh muscles (Fig. 2). Immu-
nohistochemically, red-colored cells indicating PKH26-
positive MSCs were surrounded by a green color
suggesting local secretion of bFGF and VEGF from the
MSCs (Fig. 3A and B).
NGF and NT-3 contents in soleus muscles. NGF con-
tents in the soleus muscles of the saline-injected side of
STZ-induced diabetic rats (497 
 76 pg/mg protein, P 
0.0070) were signiﬁcantly reduced compared with those of
normal rats (1,084 
 465 pg/mg protein). MSC transplan-
tation did not improve the reduced NGF contents in
STZ-induced diabetic rats (Fig. 4A). Similarly, NT-3 con-
tents were signiﬁcantly decreased in the saline-injected
side of STZ-induced diabetic rats (271 
 46 pg/mg protein,
P  0.0020) compared with those of normal rats (555 

161 pg/mg protein), and transplantation of MSCs did not
show any effects on the NT-3 contents (Fig. 4B).
Measurement of current perception threshold. The
current perception threshold at 5 and 250 Hz tended to be
decreased in 4-week STZ-induced diabetic rats compared
with that in age-matched normal rats, but the differences
were not signiﬁcant (Fig. 5A). At 8 weeks, there were no
signiﬁcant differences in the current perception threshold
at 5, 250, or 2,000 Hz between STZ-induced diabetic rats
and age-matched normal rats (Fig. 5B). In 12-week STZ-
induced diabetic rats, the current perception threshold at
5 Hz in the saline-injected limb was signiﬁcantly increased
compared with that in normal rats (normal: 0.22 
 0.06
mA, diabetic-saline: 0.31 
 0.06 mA; P  0.0016), repre-
senting hypoalgesia in the STZ-induced diabetic rats. In
the MSC-transplanted limb, this deterioration in sensation
was normalized (diabetic-MSCs: 0.22 
 0.03 mA, P 
0.0022). Similar results were obtained with a pulse at 250
Hz. The current perception threshold at 250 Hz in the
saline-injected limb was signiﬁcantly increased compared
with that in normal rats (normal: 0.21 
 0.05 mA, diabetic-
A Saline B PKH26(+) MSCs
x100 x100
FIG. 1. Tracking of transplanted MSCs. A: Saline-injected muscle. B:
PKH26-positive MSC-injected muscle. Four weeks after transplanta-
tion, PKH26-positive MSCs were mainly observed in the gap between
muscle ﬁbers. (Please see http://dx.doi.org/10.2337/db008-0031 for a
high-quality digital representation of this ﬁgure.)
FIG. 2. bFGF and VEGF mRNA expressions in saline- or MSC-injected muscle. A: Expression of bFGF in thigh muscles. B: Expression of VEGF
in thigh muscles. Results are means  SD. *P < 0.01 vs. STZ-induced diabetic rats treated with saline alone.
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 0.19 mA; P  0.0001). In the MSC-trans-
planted limb, this deﬁcit was signiﬁcantly prevented
(diabetic-MSCs: 0.25 
 0.06 mA; P  0.0003). On the other
hand, 12-week STZ-induced diabetic rats showed no alter-
ation in the current perception threshold at 2,000 Hz. The
injection of MSCs into normal rats did not induce signiﬁ-
cant changes in the current perception threshold at 5, 250,
or 2,000 Hz (Fig. 5C).
Effects of MSC transplantation on MNCV. The MNCV
in the sciatic-tibial nerves of 8-week STZ-induced diabetic
rats was signiﬁcantly delayed compared with that of
normal rats (normal: 54.6 
 2.5 m/s, diabetic: 38.1 
 3.3;
P  0.0080) (Fig. 6A). The delayed MNCV in the saline-
injected limb (37.6 
 3.4 m/s) of 12-week STZ-induced
diabetic rats was signiﬁcantly ameliorated by MSC trans-
plantation (46.8 
 5.5 m/s, P  0.0042) (Fig. 6B). However,
MSC transplantation did not alter the MNCV of the sciatic-
tibial nerves in the normal rats.
Effects of MSC transplantation on SNBF. SNBF in
8-week STZ-induced diabetic rats was signiﬁcantly de-
creased compared with that in normal rats (normal: 21.7 

3.2 ml  min
1  100 g
1, diabetic: 8.3 
 3.9 ml  min
1  100
g
1; P  0.0001) (Fig. 7A). The decrease in the SNBF in
12-week STZ-induced diabetic rats (9.2 
 5.3 ml  min
1 
100 g
1) was signiﬁcantly ameliorated (18.2 
 5.3 ml 
min
1  100 g
1, P  0.0081) by MSC transplantation (Fig.
7B). However, MSC transplantation induced no alteration
of the SNBF in normal rats.
Capillary number–to–muscle ﬁber ratio. The vascula-
tures were visualized by von Willebrand factor immuno-
staining, a speciﬁc marker for endothelial cells.
Quantitative analyses revealed that the capillary number–
to–muscle ﬁber ratio in the saline-injected side of STZ-
induced diabetic rats (0.38 
 0.04, P  0.0011) was
signiﬁcantly reduced compared with that of normal rats
(0.53 
 0.05). Transplantation of MSCs signiﬁcantly aug-
mented the ratio (0.55 
 0.08, P  0.0001) compared with
the saline-injected side in STZ-induced diabetic rats (Fig.
7C). Transplantation of MSCs into normal rats showed no
signiﬁcant differences.
Morphometry of sural nerves. The results of the my-
elinated ﬁber morphometry of sural nerves are shown in
Table 1. Twelve-week STZ-induced diabetic rats showed
no changes in ﬁber number, axonal size, myelin area, or
PKH26
bFGF
DAPI
Merge
x1000
PKH26
VEGF
DAPI
Merge
x1000
FIG. 3. Secretion of bFGF and VEGF by transplanted MSCs. A: Colocalization of PKH26-positive MSCs and bFGF in soleus muscles 4 weeks after
transplantation. PKH26-positive MSCs (red, top left), bFGF staining (green, middle left), and DAPI staining of nuclei (blue, bottom left) are
shown. PKH26-positive MSCs are surrounded by green color, indicating secretion of bFGF from MSCs (Merge, right). B: Colocalization of
PKH26-positive MSCs and VEGF in soleus muscles. PKH26-positive MSCs (red, top left), VEGF staining (green, middle left), and DAPI staining
of nuclei (blue, bottom left) are shown. PKH26-positive MSCs are surrounded by green color, suggesting that MSCs secreted VEGF at the injected
site (Merge, right). (Please see http://dx.doi.org/10.2337/db008-0031 for a high-quality digital representation of this ﬁgure.)
FIG. 4. Evaluations of NGF (A) and NT-3 (B) protein content in soleus muscles by enzyme-linked immunosorbent assay. Protein contents were
expressed as picograms per milligram protein. Results are means  SD. *P < 0.01 vs. normal rats.
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larity in the saline-injected limbs of STZ-induced dia-
betic rats (0.771 
 0.011, P  0.0047) was signiﬁcantly
decreased compared with that of normal rats (0.794 

0.008). In the MSC-transplanted limb, this decrement
was normalized (0.796 
 0.009, P  0.0003). MSC
transplantation did not alter the axonal circularity in
normal rats.
Neuroﬁlament contents in sural nerves. The protein
contents of NF-H, NF-M, and NF-L in distal sural nerves were
similarly decreased in the saline-injected limbs of 12-week
STZ-induced diabetic rats (P  0.0001). This decrease was
fully prevented by the transplantation of MSCs (P  0.0001)
(Fig. 8). In normal rats, the transplantation of MSCs induced
no alterations in the neuroﬁlament contents.
DISCUSSION
The present study demonstrated that transplantation of
MSCs improved hypoalgesia, delayed MNCV, reduced
SNBF, and decreased axonal circularity in diabetic nerves
of the treated limbs. The immunohistological study re-
vealed that the capillary number–to–muscle ﬁber ratio
were increased in the MSC-injected hind limb skeletal
muscles. Four weeks after the transplantation, MSCs
FIG. 5. Evaluation of sensory nerve functions. Measurement of current perception threshold at 2,000, 250, and 5 Hz by the neurometer was
performed on 4-week (A), 8-week (B), and 12-week (C) STZ-induced diabetic rats. Results are means  SD. *P < 0.01 vs. normal rats; **P <
0.0001 vs. normal rats; †P < 0.01 vs. STZ-induced diabetic rats treated with saline; ††P < 0.001 vs. STZ-induced diabetic rats treated with saline.
FIG. 6. MNCV in sciatic-tibial nerves of normal and STZ-induced
diabetic rats. MNCV was measured in 8 (A) and 12 (B) weeks of
diabetes. Results are means  SD. *P < 0.01 vs. normal rats; †P < 0.01
vs. STZ-induced diabetic rats treated with saline.
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tors such as VEGF and bFGF at the injected sites.
In previous studies, MSCs have been shown to differen-
tiate into a number of mesenchymal cell types, including
osteoblasts, chondrocytes, and adipocytes (8). Addition-
ally, MSCs have been reported to have the potential to
differentiate into neural cells, such as astrocytes (22),
oligodendrocytes (23), and Schwann cells (24,25). More-
over, several subpopulations of bone marrow, including
MSCs, are speculated to differentiate into the cellular
components of vascular structures (14,26–29). In this
study, MSCs stayed in the gap between muscle ﬁbers at
transplanted sites and were not incorporated into tissue
structures of recipient animals. These results indicate that
the therapeutic effects obtained in this study were not
mediated through the differentiation or fusion of MSCs.
On the other hand, MSCs have been reported to secrete
a wide array of cytokines, such as bFGF, VEGF, monocyte
chemoattractant protein-1, and stem cell–derived factor-1
(12). In fact, MSC transplantation has been performed in
the ﬁeld of ischemic diseases, and it has been suggested
that its plausible effects would be mediated largely
through paracrine actions of locally released arteriogenic
cytokines, including bFGF and VEGF (11,13,30). Although
bFGF or VEGF has the independent ability to induce
angiogenesis, the use of bFGF and VEGF in a coordinated
manner has been shown to induce functional neovascular-
ization (31). Furthermore, bFGF and VEGF have been
reported to have neurosupportive effects (5,6). In our
study, bFGF and VEGF mRNA expressions in STZ-induced
diabetic rats were upregulated in MSC-injected hind limb
muscles, and MSCs maintained their viabilities and abili-
ties to secrete bFGF and VEGF even 4 weeks after the
transplantation. These observations suggest that the inter-
ventional effects of MSC transplantation on DPN demon-
strated here would be achieved, for the most part, by the
paracrine actions of bFGF and VEGF, and these cytokines
would work as both angiogenic and neurotrophic factors.
We also evaluated the protein levels of VEGF in the soleus
muscles using a commercially available enzyme-linked
immunosorbent assay kit. The VEGF content was de-
creased in the saline-treated limbs of 12-week STZ-induced
diabetic rats (normal-saline: 68.4 
 13.8 pg/mg protein,
normal-MSCs: 62.8 
 13.7 pg/mg protein, diabetic-saline:
28.0 
 16.3 pg/mg protein), which is consistent with a
previous report by Schratzberger et al. (6). Although this
decrease was not signiﬁcantly ameliorated by the trans-
plantation of MSCs, the protein content of VEGF tended to
increase (diabetic-MSCs: 48.0 
 13.3 pg/mg protein) and
was accompanied by the increased mRNA expression of
VEGF. The protein contents of bFGF could not be mea-
sured, but it can be speculated that MSC transplantation
would have effects on the protein content of bFGF similar
to those of VEGF. Therefore, VEGF and bFGF secreted by
the transplanted MSCs would additively exert angiogenic
and neurotrophic actions.
Longitudinal and further studies are required to assess
how long MSCs work in the injected sites and whether
they differentiate and incorporate into several tissues or
not. The contributions of other potential cytokines, such
as monocyte chemoattractant protein-1 or stem cell–
derived factor-1, on DPN should be also evaluated.
Our study revealed that the capillary number–to–muscle
ﬁber ratio in the hind limb skeletal muscles were signiﬁ-
cantly lower in STZ-induced diabetic rats than in normal
rats, which is consistent with human studies (32), and
MSC transplantation induced neovascularization. The
level of therapeutic vasculogenesis induced by MSC trans-
plantation was similar to that by endothelial progenitor
cell transplantation, as we previously reported (16), and
the differentiation or incorporation of MSCs to vessels was
not observed, suggesting that neovasculalization induced
by transplantation would be mediated through the actions
of angiogenic factors such as VEGF and bFGF secreted
from MSCs, which would explain the improvement of
NBF. In addition, both VEGF and bFGF have been re-
ported to induce endothelial nitric oxide synthase (eNOS)
production and to increase local blood ﬂow through
vasodilatation. Although we did not assess the eNOS levels
in vasa nervorum, mRNA expressions of bFGF and VEGF
were measured in the soleus muscles. Both expressions
were signiﬁcantly elevated in the MSC-transplanted limbs
of STZ-induced diabetic rats but not in those of normal
rats. Therefore, eNOS production could be induced in the
MSC-transplanted limbs of STZ-induced diabetic rats.
Thus, both the induction of eNOS production and angio-
genesis by MSCs would ameliorate impaired NBF of
sciatic nerves in STZ-induced diabetic rats. However, it
remains unknown why MSC transplantation did not have
any effects on mRNA expressions of bFGF and VEGF or
NBF in normal rats. It can be speculated that diabetic
conditions such as hyperglycemia and impaired local
FIG. 7. SNBF and capillary number–to–muscle ﬁber ratio in normal and STZ-induced diabetic rats. SNBF was measured in 8- (A) and 12- (B) week
STZ-induced diabetic rats. Capillary number–to–muscle ﬁber ratio in skeletal muscles (C) were measured 4 weeks after MSC transplantation.
Results are means  SD. *P < 0.0001 vs. normal rats; †P < 0.01 vs. STZ-induced diabetic rats treated with saline.
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MSCs to more strongly produce and secrete bFGF and
VEGF. Further studies are in progress in our laboratory.
The impairment of NBF is one of the major pathogenic
factors in the development of DPN. This notion is clini-
cally and experimentally supported by various studies,
which reported that the amelioration of NBF by various
treatments improved impaired nerve functions (16,17,33–
40). The beneﬁcial effects of MSC transplantation on NCV
and NBF in this study could be comparable with those of
the therapeutic modalities reported previously. However,
there is disagreement as to whether reduced NBF can
account for diabetic neuropathy (41,42). Other factors
including neurotrophic factors such as NGF and NT-3
could be involved in the improvement of NCV. In the present
study, NGF and NT-3 protein contents were reduced in hind
limb muscles of STZ-induced diabetic rats, consistent with
previous works that demonstrated the role of these neuro-
trophines in DPN (43,44). However, MSC transplantation
improved NCV without affecting the protein levels of NGF
and NT-3 in hind limb muscles of STZ-induced diabetic rats.
Therefore, the therapeutic effects of MSC transplantation on
NCV would not be mediated through NGF or NT-3. As
mentioned above, it can be speculated that VEGF and bFGF
supplied by transplanted MSCs contributed to the improve-
ment of NCV through the amelioration of NBF or direct
actions to axons and Schwann cells.
In the present study, we evaluated sensory nerve func-
tions using a CPT/LAB neurometer. The neurometer is a
device that measures selectively the current perception
thresholds in three classes of afferent ﬁbers by applying
transcutanous sine-wave stimuli at three frequencies of
2,000, 250, and 5 Hz via surface electrodes at a current
intensity in the range of 0.01–9.9 mA to the skin. The
pulses at 2,000, 250, and 5 Hz mainly stimulate large
myelinated (A	-), small myelinated (A-), and small unmy-
elinated (C-) ﬁbers, respectively. The neurometer is now
widely used clinically to evaluate the effects of analgesic
drugs and peripheral nerve function in various painful
neuropathies, including DPN (45–48). Although previous
studies (15,49–51) reported methods for measurement of
the current perception threshold with the neurometer in
rats and sensory nerve functions in animals, no studies
have evaluated STZ-induced diabetic animals. This is the
ﬁrst report that evaluates DPN in rats using the neurom-
eter. Twelve weeks after the induction of diabetes, STZ-
induced diabetic rats showed no abnormalities in the
current perception threshold at 2,000 Hz. However, hy-
poalgesia at 5 and 250 Hz were observed in the STZ-
induced diabetic rats, and transplantation of MSCs
improved this abnormality. These results are consistent
with clinical ﬁndings that an impairment of small ﬁbers
occurs as an earlier event than that of large ﬁbers in the
natural history of DPN (52–54). However, STZ-induced
diabetic rats did not show hyperalgesia at 4 weeks of
diabetes, in contrast with previous reports that evaluated
small ﬁber functions of STZ-induced diabetic rats using
conventional testing methods, such as a thermal plantar
test. Calcutt et al. (55) reported that STZ-induced diabetic
rats showed thermal hyperalgesia at 4 weeks of diabetes.
In this study, there was a tendency of hyperalgesia for 5-
and 250-Hz stimulations at 4 weeks of diabetes, but the
differences were not signiﬁcant. The animals were re-
strained in Ballman cages and kept under unusual stress
during the measurements. This factor could affect the
sensory function. Thus, we can speculate that the current
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not be suitable for evaluating hyperalgesia in STZ-induced
diabetic animal models. In the morphometry of sural
nerves, myelinated ﬁber loss or atrophy was not observed
in the saline-injected limbs of 12-week STZ-induced dia-
betic rats. However, the axonal circularity was signiﬁ-
cantly decreased compared with that in normal rats.
Additionally, we demonstrated that the protein contents of
NF-H, NF-M, and NF-L in distal sural nerves were decreased
in the saline-injected limbs of STZ-induced diabetic rats.
These results are in agreement with previous studies that
showed a relationship between neuroﬁlament deﬁcits and
distorted circularity (56). Therefore, we suggest that the
axonal degeneration in STZ-induced diabetic rats was re-
ﬂected by the distorted circularity and decreased NF-H,
NF-M, and NF-L in the distal sural nerves of STZ-induced
diabetic rats. In the MSC-transplanted limbs of STZ-induced
diabetic rats, both the impaired circularity and reduced
protein contents of the neuroﬁlaments were almost normal-
ized by MSC transplantation and were accompanied by
ameliorated nerve functions. However, the precise relation-
ships between neuroﬁlament deﬁcits, distorted circularity,
and functional measurements remain unknown.
Transplantation of MSCs did not have any effects on the
nerve functions or SNBF on the opposite side, and trans-
planted MSCs remained at the transplanted sites. These
results suggest that local transplantation of MSCs has no
systemic effects. In the transplanted sites, MSCs did not
construct ectopic abnormal tissues, including tumorous
growths.
In conclusion, we have demonstrated the beneﬁcial
effects of transplantation of MSCs on DPN. MSCs are
relatively easy to obtain and can be expanded to sufﬁcient
numbers for cell therapy. Although further studies de-
signed to reveal other useful aspects of MSC transplanta-
tion on DPN might be required, transplantation of MSCs
appears promising as a therapeutic strategy for DPN.
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